Macroscopic assessment of protective effect of cryopreserved placenta extract in ibuprofen-induced gastroenterocolonopathy

Abstract

Background. Over-the-counter use of nonsteroidal anti-inflammatory drugs leads to their uncontrolled consumption among the population, which in some cases makes it impossible to prevent and timely detect adverse drug effects, and their effectiveness does not always satisfy clinicians. The purpose was to characterize the cytoprotective properties of cryopreserved placenta extract according to the condition of the mucous membrane of the proximal (esophagus and stomach) and distal (small and large intestine) parts of the gastrointestinal tract on the model of ibuprofen-induced esophagogastroenterocolonopathy. Mate­rials and methods. In vivo experimental studies were performed on 28 male rats. Subchronic ibuprofen-induced gastrointestinal lesions were reproduced by intragastric administration of ibuprofen to rats at a dose of 310 mg/kg. The condition of the gastrointestinal tract mucous membrane was assessed macroscopically on a scale. Results. The therapeutic and prophylactic efficacy of esomeprazole statistically significantly (р < 0.05) took place in the proximal parts of the gastrointestinal tract but had little effect on the prevalence of ulcerative lesions in the intestine. At the same time, unlike esomeprazole, which is known to have only gastroprotective activity, cryopreserved placenta extract had a cytoprotective effect both in the stomach and in the distal parts of the gastrointestinal tract — small and large intestine. Thus, the prevalence of ibuprofen-induced both entero- and colonopathy on the background of the study of the extract was almost twice lower than in rats that did not receive correction drugs. Conclusions. It is established that the use of cryopreserved placenta extract in the treatment-and-prophylactic mode has comparable to esomeprazole gastroprotective activity. In addition, it was found that the use of the studied cryoextract was accompanied by a decrease in the multiplicity of ulcerative defects in the small and large intestine of rats, by 4.6 and 3.8 times, respectively, compared to the control animals.

Sex differences in the hepatotropic effects of antiulcer drugs and placenta cryoextract in an experimental rat liver injury model

“…It supports processes such as trophic interactions and protein synthesis, gas exchange, hormone secretion, blood pressure regulation, blood clotting, detoxification, metabolite excretion, deposition of biologically active substances, immune regulation, regulation of lipid peroxidation and more. [8][9][10] The aim of the study was to characterise the sex-specific features of the hepatotropic effects of anti-ulcer agents and placental cryoextract in the context of experimental chronic liver injury.…”

Placenta Cryoextract Is the First Ukrainian Biotechnological Anti-Ulcer Agent (Review of the Literature and Own Research)

“…Так у щурів, яким вводили КЕП ВІ статистично вірогідно (р < 0,05) знизився на 30,0 % та становив відповідно 3,0 ум.од. Ерозії та геморагії СОШ відмічені лише у 42,9 % тварин, яким вводили КЕП, в той час як у нелікованих тварин ці зміни спостерігались у 100% щурів У серії досліджень [21][22][23][24][25][26][27][28][29][30][31][32] проведеної дослідження здатності КЕП нівелювати ульцерогенну дію нестероїдних протизапальних засобів (НПЗЗ). Так, у роботі [21,22] переконливо продемонстровано, що на тлі профілактичного введення ПВА КЕП становила 69,1 % при гострій індометацин-індукованій гастропатії (ВІ = 3,5 та 1,08 відповідно у щурів контрольної групи та у щурів, яким вводили КЕП).…”

“…Застосування КЕП у лікувально-профілактичному режимі супроводжувалось співставною ПВА на моделях субхронічних ібупрофен-індукованій та ацетилсаліциловій гастропатіях та становила 72,8 % та 70,6 % відповідно [31,32].…”